Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms
- PMID: 34092788
- DOI: 10.1038/s10038-021-00940-y
Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms
Abstract
There are numerous histological subtypes (histotypes) of gynecological malignancies, with each histotype considered to largely reflect a feature of the "cell of origin," and to be tightly linked with the clinical behavior and biological phenotype of the tumor. The recent advances in massive parallel sequencing technologies have provided a more complete picture of the range of the genomic alterations that can persist within individual tumors, and have highlighted the types and frequencies of driver-gene mutations and molecular subtypes often associated with these histotypes. Several large-scale genomic cohorts, including the Cancer Genome Atlas (TCGA), have been used to characterize the genomic features of a range of gynecological malignancies, including high-grade serous ovarian carcinoma, uterine corpus endometrial carcinoma, uterine cervical carcinoma, and uterine carcinosarcoma. These datasets have also been pivotal in identifying clinically relevant molecular targets and biomarkers, and in the construction of molecular subtyping schemes. In addition, the recent widespread use of clinical sequencing for the more ubiquitous types of gynecological cancer has manifested in a series of large genomic datasets that have allowed the characterization of the genomes, driver mutations, and histotypes of even rare cancer types, with sufficient statistical power. Here, we review the field of gynecological cancer, and seek to describe the genomic features by histotype. We also will demonstrate how these are linked with clinicopathological attributes and highlight the potential tumorigenic mechanisms.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.
Similar articles
-
Histotype-specific copy-number alterations in ovarian cancer.BMC Med Genomics. 2012 Oct 18;5:47. doi: 10.1186/1755-8794-5-47. BMC Med Genomics. 2012. PMID: 23078675 Free PMC article.
-
Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data.J Biomed Semantics. 2017 Sep 19;8(1):40. doi: 10.1186/s13326-017-0146-9. J Biomed Semantics. 2017. PMID: 28927463 Free PMC article.
-
Molecular Genetics of Endometrial Carcinoma.Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
-
Molecular genetics of gynecologic cancer.J Korean Med Sci. 1997 Oct;12(5):383-9. doi: 10.3346/jkms.1997.12.5.383. J Korean Med Sci. 1997. PMID: 9364294 Free PMC article. Review.
-
Race-associated molecular changes in gynecologic malignancies.Cancer Res Commun. 2022 Feb;2(2):99-109. doi: 10.1158/2767-9764.crc-21-0018. Epub 2022 Feb 17. Cancer Res Commun. 2022. PMID: 35992327 Free PMC article.
Cited by
-
Uterine Carcinosarcoma (UCS): A Literature Review and Survival Analysis from a Retrospective Cohort Study.Cancers (Basel). 2024 Nov 21;16(23):3905. doi: 10.3390/cancers16233905. Cancers (Basel). 2024. PMID: 39682097 Free PMC article.
-
Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.J Transl Med. 2022 Feb 2;20(1):65. doi: 10.1186/s12967-022-03259-0. J Transl Med. 2022. PMID: 35109853 Free PMC article.
-
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.Curr Oncol. 2021 Nov 20;28(6):4862-4873. doi: 10.3390/curroncol28060410. Curr Oncol. 2021. PMID: 34898589 Free PMC article.
-
Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors.Diagnostics (Basel). 2022 Aug 6;12(8):1903. doi: 10.3390/diagnostics12081903. Diagnostics (Basel). 2022. PMID: 36010253 Free PMC article.
-
Role of signaling pathways in endometrial cancer.Mol Biol Rep. 2025 Apr 21;52(1):408. doi: 10.1007/s11033-025-10523-1. Mol Biol Rep. 2025. PMID: 40257522 Review.
References
-
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. - DOI
-
- Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. - DOI
-
- Cancer Genome Atlas Research Network, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H,et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84. - DOI
Publication types
MeSH terms
Grants and funding
- JP15K06861/MEXT | Japan Society for the Promotion of Science (JSPS)
- JP18K07338/MEXT | Japan Society for the Promotion of Science (JSPS)
- JP26462543/MEXT | Japan Society for the Promotion of Science (JSPS)
- JP17K11308/MEXT | Japan Society for the Promotion of Science (JSPS)
- 5144/Vehicle Racing Commemorative Foundation